

**MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE MEETING
PREFERRED DRUG LIST MEETING
MEETING SCHEDULED**

Friday, April 16, 2010
8:00a.m. – 12:00p.m

**Frontier Building, 3601 "C" Street; Room 890/896
Anchorage, Alaska**

The public is invited to attend this meeting and give public comment. The Department has developed a new method for class review to better utilize the time of the P&T Committee. Three sets of classes are up for review. For classes shown with '1' are new classes or classes where new information exists and public testimony will be taken. Classes shown with '2' will be reviewed only if new information is received, then public testimony will be taken. Classes shown with '3', no changes are recommended and no public testimony will be taken. New information includes: new drugs or indications, new warnings or new head to head clinical evidence.

The drug classes to be discussed include:

Re review Ophthalmic Anti-allergy–2	Re-review Inhaled Steroids–3	Re-review Ophthalmic Quinolones–2
Re-review Anti-emetics–2	Review Intranasal Antihistamines–1	Re-review Oral Anti-Herpes–2
Re-review Anti-migraine–3	Re-review Leukotriene Modifiers–2	Re-review Oral Onychomycosis–3
Re-review Long Acting Beta Agonists–2	Re-review Low Sedating Antihistamines–2	Re-review Oral Quinolones 2/3 Gen–2
Re-review Short Acting Beta Agonists–3	Re-review Macrolides–3	Re-review Otic Quinolones–2
Re-review Cephalosporins 2/3 Gen–3	Re-review Nasal Steroids–3	Review Topical Antibiotics–1
Re-review COPD Inhalants–2	Re-review Ophthalmic Immunomodulator–3	Re-review Topical Anti-fungal–2
Review Hepatitis B – Oral–1	Re-review Ophthalmic Mast Cell Stabilizer–3	Re-review Topical Anti-viral–3
Re-review Hepatitis C–3	Re-review Ophthalmic NSAIDS–2	

Clinical information for dissemination to the Pharmacy and Therapeutics Committee needs to be sent to Melinda Sater, PharmD by March 15, 2010 at First Health Services Corporation, 1835 S. Bragaw, Suite 200, Anchorage, AK 99508 or call 1-907-644-6805. See Clinical Submission Form at <http://hss.state.ak.us/dhcs/PDL/default.htm>

If you are unable to attend in person, you may join via teleconference by calling: 1-800-315-6338. Use access code 735#.

Time will be allowed for public comment during the meeting. For information on making public comments to the Committee, or to obtain an agenda please call (907) 334-2400.

If you are a person with a disability who needs a special modification in order to participate, please call (907) 334-2400 no later than 2:00 p.m., Thursday, April 15, 2010, to make necessary arrangements.